BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Kwong AJ, Kwo PY. Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Aliment Pharmacol Ther 2020;51:739-40. [PMID: 32162374 DOI: 10.1111/apt.15656] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Igelström E, Campbell M, Craig P, Katikireddi SV. Cochrane's risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: A methodological systematic review. J Clin Epidemiol 2021;140:22-32. [PMID: 34437948 DOI: 10.1016/j.jclinepi.2021.08.022] [Reference Citation Analysis]
4 Huang SC, Kao JH. Strategies for hepatitis C virus treatment failure. J Formos Med Assoc 2021:S0929-6646(21)00426-5. [PMID: 34538553 DOI: 10.1016/j.jfma.2021.09.004] [Reference Citation Analysis]
5 Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc 2020;119:1593-600. [PMID: 32839045 DOI: 10.1016/j.jfma.2020.08.010] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu X, Hu P. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. J Clin Transl Hepatol 2021;9:125-32. [PMID: 33604263 DOI: 10.14218/JCTH.2020.00078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology 2021;74:1472-82. [DOI: 10.1016/j.jhep.2021.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
8 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
9 Wang X, Wei L. Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. J Clin Transl Hepatol 2021;9:419-27. [PMID: 34221928 DOI: 10.14218/JCTH.2020.00097] [Reference Citation Analysis]
10 de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. J Antimicrob Chemother 2020;75:3349-58. [PMID: 32772078 DOI: 10.1093/jac/dkaa304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]